There were no statistically significant differences between the groups in terms of sex distribution, presence of diabetes or hypertension, or the use of renin–angiotensin system (RAS) blockers, beta-blockers, calcium channel blockers, statins, aspirin, or SGLT2 inhibitors (all p > 0.05). Here, SLC5A2 is linked to diabetes mellitus.